COLLEGIUM PHARMACEUTICAL, INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
COLL$24.47-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $231,252 | $70,565 |
| Marketable securities | 155,427 | 92,198 |
| Accounts receivable, net | 211,328 | 228,540 |
| Inventory | 40,912 | 35,560 |
| Prepaid expenses and other current assets | 32,642 | 30,394 |
| Restricted cash | 19,850 | 25,000 |
| Total current assets | 691,411 | 482,257 |
| Property and equipment, net | 12,013 | 14,329 |
| Operating lease right-of-use assets | 4,187 | 5,822 |
| Intangible assets, net | 669,510 | 891,402 |
| Restricted cash | 1,056 | 1,047 |
| Deferred tax assets | 112,539 | 98,033 |
| Other noncurrent assets | 20,193 | 8,368 |
| Goodwill | 145,925 | 162,333 |
| Total assets | $1,656,834 | $1,663,591 |
| Liabilities and shareholders' equity | ||
| Current liabilities | ||
| Accounts payable | $10,659 | $3,934 |
| Accrued liabilities | 62,464 | 72,124 |
| Accrued rebates, returns and discounts | 318,266 | 338,642 |
| Current portion of term notes payable | 29,000 | 64,583 |
| Current portion of operating lease liabilities | 1,407 | 1,271 |
| Business combination consideration payable | 17,565 | 28,956 |
| Deferred revenue | 667 | — |
| Total current liabilities | 440,028 | 509,510 |
| Term notes payable, net of current portion | 542,112 | 550,733 |
| Convertible senior notes | 238,213 | 237,172 |
| Operating lease liabilities, net of current portion | 4,132 | 5,539 |
| Deferred royalty obligation | 121,563 | 120,613 |
| Deferred revenue, net of current portion | 9,111 | 10,000 |
| Contingent consideration | — | 1,182 |
| Total liabilities | 1,355,159 | 1,434,749 |
| Commitments and contingencies (refer to Note 13) | ||
| Shareholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares - 5,000,000 | — | — |
| Common stock, $0.001 par value; authorized shares - 100,000,000; 40,736,330 issued and 31,707,608 outstanding shares as of December 31, 2025 and 39,646,749 issued and 31,440,155 outstanding shares as of December 31, 2024 | 41 | 40 |
| Additional paid-in capital | 624,954 | 590,251 |
| Treasury stock, at cost; 9,028,722 shares as of December 31, 2025 and 8,206,594 shares as of December 31, 2024 | (222,510) | (197,505) |
| Accumulated other comprehensive income | 319 | 55 |
| Accumulated deficit | (101,129) | (163,999) |
| Total shareholders’ equity | 301,675 | 228,842 |
| Total liabilities and shareholders’ equity | $1,656,834 | $1,663,591 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.